Pyrrolidine

Pyrrolidine

SCHEMBL286006

C1CCC2=NCCCN2CC1.C1CCNC1

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INMT O95050 4/20 0.78
USP2 O75604 2/20 0.78
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HRH1 P35367 1/20 0.42
ALDH1A1 P00352 2/20 0.33
CASP1 P29466 1/20 0.33
CASP4 P49662 1/20 0.33
CASP5 P51878 1/20 0.33
ACHE P22303 3/20 0.33
HRH4 Q9H3N8 1/20 0.33
KDM4E B2RXH2 1/20 0.32
CHRM3 P20309 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31
SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperidine SCHEMBL17713174 1.00 INMT (0.78) INMTUSP2SMN1; SMN2TDP1HRH1
SCHEMBL2734323 0.88 INMT (1.00) INMTUSP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL17417853 0.88 INMT (1.00) INMTUSP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL3047 0.88 INMT (1.00) INMTUSP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL6853620 0.88 INMT (1.00) INMTUSP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL10601682 0.88 INMT (1.00) INMTUSP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL16583523 0.88 INMT (1.00) INMTUSP2SMN1; SMN2TDP1ALDH1A1
SCHEMBL2401189 0.88 INMT (1.00) INMTUSP2SMN1; SMN2TDP1ALDH1A1
Iodide SCHEMBL23365018 0.86 INMT (0.95) INMTUSP2SMN1; SMN2TDP1ALDH1A1
Fluoride SCHEMBL14777947 0.86 INMT (0.95) INMTUSP2SMN1; SMN2TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311946-A1 Solid Phase Peptide for the Production of Goserelin MALLINCKRODT INC. (US) 2010-12-09 US claimed
US-8742028-B2 Solid support for Fmoc-solid phase synthesis of peptide acids MALLINCKRODT LLC (US) 2014-06-03 US disclosed
EP-2215106-B1 INDOLE GRAFTED SOLID SUPPORT FOR FMOC-SOLID PHASE PEPTIDE SYNTHESIS MALLINCKRODT LLC (US) 2013-02-13 EP disclosed
EP-2427474-A1 SOLID SUPPORT FOR FMOC-SOLID PHASE SYNTHESIS OF PEPTIDE ACIDS Mallinckrodt LLC (US) 2012-03-14 EP disclosed
WO-2011011342-A1 SYNTHESIS OF DESMOPRESSIN MALLINCKRODT INC. (US) 2011-01-27 WO disclosed
US-20100311946-A1 Solid Phase Peptide for the Production of Goserelin MALLINCKRODT INC. (US) 2010-12-09 US disclosed
WO-2010141276-A1 SOLID PHASE PEPTIDE SYNTHESIS PROCESS FOR THE PRODUCTION OF GOSERELIN MALLINCKRODT INC. (US) 2010-12-09 WO disclosed
US-20100286359-A1 Solid Support for FMOC-Solid Phase Synthesis of Peptide Acids MALLINCKRODT INC. (US) 2010-11-11 US disclosed
WO-2010129520-A1 SOLID SUPPORT FOR FMOC-SOLID PHASE SYNTHESIS OF PEPTIDE ACIDS MALLINCKRODT INC. (US) 2010-11-11 WO disclosed
EP-2215106-A1 INDOLE GRAFTED SOLID SUPPORT FOR FMOC-SOLID PHASE PEPTIDE SYNTHESIS Mallinckrodt Inc. (US) 2010-08-11 EP disclosed
US-7714063-B2 Solid support for Fmoc-solid phase synthesis of peptides MALLINCKRODT INC. (US) 2010-05-11 US disclosed
WO-2009064637-A1 INDOLE GRAFTED SOLID SUPPORT FOR FMOC-SOLID PHASE PEPTIDE SYNTHESIS MALLINCKRODT INC. (US) 2009-05-22 WO disclosed
US-20090131587-A1 Solid Support for Fmoc-Solid Phase Synthesis of Peptides MALLINCKRODT INC. (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311946-A1 Solid Phase Peptide for the Production of Goserelin GCG, GNRHR, GIPR INMT 539/4885USP2 1800/4885SMN1; SMN2 3188/4885
US-20090131587-A1 Solid Support for Fmoc-Solid Phase Synthesis of Peptides MAX, PTMS, ANPEP INMT 2137/4885USP2 3374/4885SMN1; SMN2 1505/4885
US-20100286359-A1 Solid Support for FMOC-Solid Phase Synthesis of Peptide Acids MAX, NPPA, PTMS INMT 2641/4885USP2 3442/4885SMN1; SMN2 1514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.